ReviewThe British journal of ophthalmology2005
Topical ciclosporin in the treatment of ocular surface disorders.
Review in The British journal of ophthalmology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Topical treatments for blepharokeratoconjunctivitis in children.The Cochrane database of systematic reviews · 2017Pooled it
- Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up.The British journal of ophthalmology · 2016Trial
- Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.Bone marrow transplantation · 2008Trial
- Nature Meets Science: The Role of Food-Grade Oils and Green Excipients in Pharmaceutical Nanoemulsion Formulation.Materials (Basel, Switzerland) · 2026Review
- Advances in the Medical Management of Pediatric Blepharokeratoconjunctivitis.Advances in therapy · 2026Review
- Article
- The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine.Clinical reviews in allergy & immunology · 2025Review
- Advancements in Nanoemulsion-Based Drug Delivery Across Different Administration Routes.Pharmaceutics · 2025Review
- Potential therapeutic effects of green tea (Heliyon · 2024Review
- Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis.Cell biochemistry and biophysics · 2024Review
- Uncommon Blepharitis.Journal of clinical medicine · 2024Article
- Overview of CFTR activators and their recent studies for dry eye disease: a review.RSC medicinal chemistry · 2023Review
- Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021).Journal of clinical and translational hepatology · 2023Article
- Synthetic Strategies for Improving Solubility: Optimization of Novel Pyrazolo[1,5-Journal of medicinal chemistry · 2023Article
- Novel CFTR Activator Cact-3 Ameliorates Ocular Surface Dysfunctions in Scopolamine-Induced Dry Eye Mice.International journal of molecular sciences · 2022Article
- A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- [Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].Zhonghua nei ke za zhi · 2021Article
- Isorhamnetin Ameliorates Dry Eye Disease via CFTR Activation in Mice.International journal of molecular sciences · 2021Article
- Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular surface diseases, with a complex interplay of genetic, environmental, and psychosocial factors. Management of these conditions is often challenging. Topical corticosteroids, with their associated side effects, are the mainstay of current treatments for patients with vision threatening disease. Ciclosporin A is an immunomodulator that specifically inhibits T lymphocyte proliferation. Recently, a topical ciclosporin preparation was approved by the US Food and Drug Administration and became available for use in ophthalmology. Given the increasing use of ciclosporin eye drops, the goal of this article is to provide the reader with an overview of the well established uses of ciclosporin and to help refine the questions that should be addressed by future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.